durvalumab + carboplatin + paclitaxel

Durvalumab + carboplatin + paclitaxel is a combination therapy that pairs the PD-L1 inhibitor durvalumab (Imfinzi) with two chemotherapy agents (carboplatin and paclitaxel). This regimen is primarily used as first-line treatment for certain types of cancer, particularly endometrial cancer. The treatment protocol typically involves initial combination therapy with all three agents followed by maintenance therapy with durvalumab alone. The combination works through complementary mechanisms: durvalumab blocks the PD-L1 protein, preventing it from interacting with PD-1 and CD80 proteins, thereby releasing immune system inhibition and enhancing anti-tumor immune responses. Meanwhile, carboplatin and paclitaxel provide direct cytotoxic effects against cancer cells through DNA damage and microtubule stabilization, respectively.

Brand names

Imfinzi + carboplatin + paclitaxel

Other names

TAXIOdurvalumab-Intergroupe Francophone de Cancerologie Thoracique-Small Cell Lung Cancer